
Silence Therapeutics plc SLN
$ 5.8
-2.36%
Annual report 2023
added 12-27-2025
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
- |
Market Cap[1] |
$ 622 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
BioNTech SE
BNTX
|
$ 91.28 | 0.11 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 3.54 | -20.81 % | $ 238 B | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 330.34 | 3.6 % | $ 43.3 B | Nasdaq Global Select Market,SPB | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Evogene Ltd.
EVGN
|
$ 0.79 | 1.22 % | $ 27.9 M | Nasdaq Global Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
argenx SE
ARGX
|
$ 748.25 | 0.25 % | $ 25 B | Nasdaq Global Select Market | ||
|
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | ||
|
Фармсинтез
LIFE
|
- | - | - | MOEX | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Aptorum Group Limited
APM
|
$ 0.89 | -4.33 % | $ 4.85 M | Nasdaq Global Select Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | ||
|
AbbVie
ABBV
|
$ 206.69 | -1.01 % | $ 366 B | NYSE,SPB | ||
|
Aquestive Therapeutics
AQST
|
$ 4.09 | -0.97 % | $ 437 M | Nasdaq Global Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | ||
|
AbCellera Biologics
ABCL
|
$ 3.39 | -3.69 % | $ 1.01 B | Nasdaq Global Select Market | ||
|
Arcturus Therapeutics Holdings
ARCT
|
$ 8.22 | 2.37 % | $ 225 M | Nasdaq Global Market,SPB | ||
|
Ardelyx
ARDX
|
$ 5.97 | 0.51 % | $ 1.44 B | Nasdaq Global Market | ||
|
Genmab A/S
GMAB
|
$ 27.75 | 0.91 % | $ 17.6 B | Nasdaq Global Select Market | ||
|
Cerevel Therapeutics Holdings
CERE
|
- | - | $ 7.29 B | Nasdaq Capital Market | ||
|
Grifols, S.A.
GRFS
|
$ 8.23 | -0.12 % | $ 6.83 B | Nasdaq Global Select Market | ||
|
Akebia Therapeutics
AKBA
|
$ 1.32 | -4.35 % | $ 339 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.